therascreen KRAS RGQ PCR Kit
The therascreen KRAS RGQ PCR Kit is a real-time, qualitative in vitro diagnostic test for the detection of 7 somatic mutations in the KRAS oncogene using a sample of DNA extracted from formalin-fixed, paraffin-embedded (FPPE) non-small cell lung cancer (NSCLC) tissue and colorectal cancer (CRC) tissue.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The therascreen KRAS RGQ PCR Kit is a real-time, qualitative in vitro diagnostic test for the detection of 7 somatic mutations in the KRAS oncogene using a sample of DNA extracted from formalin-fixed, paraffin-embedded (FPPE) non-small cell lung cancer (NSCLC) tissue and colorectal cancer (CRC) tissue.
The therascreen KRAS RGQ PCR Kit is an FDA-approved companion diagnostic (CDx) PCR test intended to aid in the identification of NSCLC patients for treatment with LUMAKRAS (sotorasib) or KRAZATI (adagrasib) based on a KRAS G12C Mutation Detected result. In addition, the kit is also an FDA-approved CDx test to aid in the selection of patients with CRC who may be eligible for treatment with Erbitux (cetuximab) or Vectibix (panitumumab), based on a KRAS No Mutation Detected test result.